Monthly Archives: May 2015


Can-Fite Phase II/III Psoriasis Success

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), announced favorable data from further analysis of its Phase II/III double-blind, placebo-controlled study designed to test the efficacy of CF101 in patients with moderate-to-severe plaque psoriasis. The study included 326 patients through 17 clinical centers in the U.S., Europe, and Israel with...
Read more

cCam Phase I for Cancer Immunotherapy

cCAM Biotherapeutics has started a Phase 1 trial assessing the effect of the CM-24 mAb on cancer patients with advanced or recurrent malignancies, including melanoma, non-small-cell lung, bladder, gastric, colorectal and ovarian cancers. The main objectives of the study are to assess the safety and tolerability of CM-24 and to...
Read more